References UK clinical guidance from the NHS, the British HIV Association (BHIVA), and the British Association for Sexual Health and HIV (BASHH). Last updated: April 2026.
Dolutegravir is an integrase strand transfer inhibitor (INSTI) that has become one of the most important HIV drugs globally. Its combination of high efficacy, high resistance barrier, good tolerability and relatively few drug interactions has made it a first-line recommendation in guidelines worldwide. It’s available as a standalone tablet (Tivicay) and in several combination products.
For a focused overview, see our Tivicay guide. This page covers dolutegravir in greater detail.
Order a discreet home HIV test
Key Facts
| Detail | Information |
|---|---|
| Class | Integrase strand transfer inhibitor (INSTI) |
| Brand name | Tivicay (standalone) |
| Combinations | Dovato, Triumeq, Juluca |
| Dose | 50mg once daily (twice daily with some interacting drugs) |
| Food requirement | None |
| Resistance barrier | Very high |
Why Dolutegravir Is Widely Recommended
- Efficacy — achieves viral suppression quickly and reliably
- Resistance — treatment-emergent resistance is exceptionally rare
- Tolerability — fewer side effects than older drug classes
- Interactions — fewer than boosted PIs, though mineral supplements need timing
- Flexibility — works as part of 2-drug and 3-drug regimens
- Cost — generic versions are available, making it affordable globally
Side Effects in Detail
Common
- Insomnia — the most frequently reported; taking in the morning may help
- Headache
- Nausea (usually mild and transient)
Less common but notable
- Weight gain — associated with INSTIs in clinical studies; mechanism not fully understood
- Neuropsychiatric effects — mood changes, anxiety, depression reported in a minority
- Creatinine rise — a lab effect from blocking renal tubular secretion, not actual kidney damage
Rare
- Hypersensitivity reaction
- Hepatotoxicity (very rare)
Special Populations
Pregnancy
Initial concerns about neural tube defects have been addressed by large observational studies showing very low absolute risk. Most guidelines now consider dolutegravir acceptable in pregnancy.
Hepatitis B co-infection
Dolutegravir does not treat hepatitis B. If co-infected, your regimen must include tenofovir. Dovato (dolutegravir + lamivudine only) is not suitable for hepatitis B co-infection.
TB treatment
If you need rifampicin for TB, the dolutegravir dose is increased to 50mg twice daily.
Dolutegravir vs Bictegravir
Both are modern INSTIs with similar efficacy and resistance profiles. Key differences:
- Dolutegravir is available standalone and in more combinations
- Bictegravir is only available in Biktarvy (with emtricitabine + TAF)
- Dolutegravir can be used in 2-drug regimens (Dovato, Juluca)
- Both are excellent first-line options
Read more: Tivicay guide | Dovato | Biktarvy
Frequently Asked Questions
Is dolutegravir the best HIV drug available?
It’s one of the most recommended worldwide. Whether it’s “best” depends on individual factors — your HIV team will choose the right drug for your situation.
Why do I need to separate antacids from dolutegravir?
Dolutegravir binds to metal ions (calcium, magnesium, iron, aluminium) in the gut, which reduces absorption. Taking them at different times prevents this.
Can I take dolutegravir if I’ve had treatment failure before?
Often yes. Dolutegravir’s high resistance barrier means it can work even in some people who have developed resistance to other drugs. Your HIV team will check your resistance profile.
Related reading
- Efavirenz for HIV: An Older NNRTI Still in Use
- Eviplera: How This Anti-HIV Drug Works
- Understanding Efavirenz in HIV Treatment
- Injectable HIV Treatment: Everything You Need to Know
- Are HIV Tests Accurate If You're on PrEP, PEP or ART?
Sources
- NHS — Sexual health conditions
- BASHH — UK clinical guidelines for STI management
- British HIV Association (BHIVA) — HIV treatment guidelines
- Terrence Higgins Trust — sexual health information
- UK Health Security Agency — STI surveillance data
Steve Page is a recognised expert on Sexually Transmitted Diseases (STDs) and STD treatments, having published numerous articles in peer-reviewed journals and presented his research at conferences around the world. He has an in-depth understanding of the latest medical research on STDs, and is an advocate for the development of new treatments and protocols to improve the health of those affected. In addition to his research, he has dedicated his career to understanding the causes and symptoms of STDs, as well as how to best treat those impacted.
